The American Academy of Pediatrics (AAP) has stated it does not support the routine use of electrocardiogram (ECG) screening before initiating treatment with stimulants for children and adolescents with attention deficit hyperactivity disorder (ADHD).
The American Academy of Pediatrics (AAP) has stated it does not support the routine use of electrocardiogram (ECG) screening before initiating treatment with stimulants for children and adolescents with attention deficit hyperactivity disorder (ADHD).
The policy statement, published in the August Pediatrics, contrasts with a recent statement made by the American Heart Association (AHA) that stated, "It is reasonable to consider adding an ECG ... to the history and physical examination in the cardiovascular evaluation of children who need to receive treatment with drugs for ADHD."1
The AAP statement argues that sudden cardiac death (SCD) in persons taking medications for ADHD is rare and occurs just as frequently in the general population of children and adolescents. In addition, the statement points out the lack of evidence supporting the routine use of ECG screening to prevent sudden death in patients before taking ADHD medications.
However, the AAP statement notes, "The AHA statement pointed out the importance of detecting silent but clinically important cardiac conditions in children and adolescents, which is a goal that the AAP shares. The primary purpose of the AHA statement is to prevent cases of SCD that may be related to stimulant medications."2
The AAP's statement is endorsed by the American Academy of Child and Adolescent Psychiatry, the Society for Developmental and Behavioral Pediatrics, the National Initiative for Children's Healthcare Quality, the National Association of Pediatric Nurse Practitioners, and Children and Adults with Attention Deficit/Hyperactivity Disorder.
References
1.Vetter VL, Elia J, Erickson C, et al: Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs. Circulation 2008;117:2407
2. Perrin JM, Friedman RA, Knilans TK, et al: Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008;122:451
Exome sequencing should be used for diagnosing cerebral palsy
October 13th 2023A systematic review and meta-analysis found that such sequencing indeed has an equivalent high genetic diagnostic yield in cerebral palsy, which supports including this neurodevelopmental disorder among those for which diagnostic exome sequencing should be used.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.